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shows a positive development within the region’s HTA. The Regional Decrees were 
impactful however the HTA reports are not fully compliant to the scoping document 
and it is central to understand the reason behind the challenge.
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Increasingly, quality of life becomes a more important part of the HTA assessments 
of new products. Assessing quality of life is trickier than changes in clinical param-
eters as changes of quality of life tend to occur slower and with a high level of 
variance. Additionally, it is sometimes necessary to assess quality of life indirectly, 
especially in cognitive disorders. However, the available data are often driven by the 
requirements for marketing authorization and rarely fit to the requests of HTA agen-
cies. Quality of life is, among mortality, morbidity and safety, one of the key patient 
relevant outcomes categories in the AMNOG (Arzneimittelmarktneuordnungsgesetz; 
Law on the Reorganization of the Pharmaceutical Market) process in Germany. 
Objectives: Our focus was to review the impact of quality of life data presented 
by manufacturers since the introduction of the AMNOG in 2011 on the level of 
additional benefit claimed by the manufacturer and the evaluation by the Federal 
Joint Committee (G-BA) and the Institute for Quality and Efficiency in Healthcare 
(IQWiG). MethOds: We screened the IMS HTA database and the assessments pub-
lished on the G-BA website for assessments including additional benefit claims 
based on quality of life. We compared these with the corresponding IQWiG reports 
and the final decision of the G-BA (if available). Results: Data on quality of life 
was part of 36 additional benefit claims. In most cases, IQWiG (n= 23) and G-BA 
(n= 28) considered quality of life data as well. However, in 6 cases IQWiG and G-BA 
assessed quality of life, even though the manufacturer didn’t include these data. 
There are only few additional benefit claims acknowledged by G-BA based on qual-
ity of life. cOnclusiOns: Even though quality of life is seen as highly relevant 
factor for the HTA assessment of a new drug or technology, it is rarely taken into 
consideration.
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Objectives: Although subgroup analysis in clinical trials is often criticized, it is still 
considered an important part of the AMNOG Dossier when describing effect modi-
fication in different patient groups. An identification of effect modification in the 
subgroups will either support or weaken the total additional benefit (Zusatznutzen) 
of a drug. The purpose of this article is to give a detailed background with regard to 
the statistical inference in subgroup analysis and a brief review of the effect of tests 
for homogeneity/interactions on the final grading of the additional benefit, accord-
ing to the decision from IQWiG. MethOds: This article covers: Understanding tests 
for homogeneity, individual versus pooled data and influence of subgroup analysis 
on recent IQWiG benefit assessment. A research of the recently published AMNOG 
Dossiers was performed. A description was given to the number of drugs that had 
an additional benefit and the subgroups that were involved. Clustering analysis 
was performed to investigate the hidden structrue in the subgroups. Regression 
models were used to analyze the relationship of the subgroups and the additional 
benefit. Results: Some subgroups such as age, gender and weight play a major role 
in the AMNOG assessment. Other subgroubs are more specific for certain disease 
areas e.g. BMI or hypertension for diabetis. In a worst case the benefit of a drug may 
disappeare when a certain subgroup is taken into consideration. cOnclusiOns: 
Subgroups exert a profound influence upon the overall effect of a drug. Despite of 
the weakness of the statistical inference, subgroup analysis plays an important role 
in the AMNOG Dossier. Some subgroups are frequently related to the overall effect 
of a drug and some might even change the whole story in the AMNOG Dossier. In 
conclusion, subgroup analysis should be understood properly and the results should 
be interpreted carefully.
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Objectives: To index six countries on the basis of the risk they pose to pharma-
ceutical prices with regards to international reference pricing (IRP), from both an 
internal (how IRP is used by the country) and external (how other countries use 
this country for IRP) perspective. MethOds: Details on IRP methodologies were 
obtained from primary and secondary research. Achievable drug price levels in 
Bulgaria, France, Germany, Portugal and Romania were derived from these mar-
kets’ IRP formula and the relative drug price levels in their reference markets 
(based on existing literature). Furthermore, based on the IRP formulas and rela-
tive drug price levels of each of the markets referencing these five and the United 
Kingdom, the markets most likely influenced by the six were identified. This num-
ber of markets, the fraction of them representing major pharmaceutical markets, 
and the relative price levels in each of the six countries were assigned weightings 
to rank them by external risk. Results: While Bulgaria, Portugal and Romania 
represent the greatest internal risk for pharmaceutical prices (i.e. greatest risk of 
obtaining a low price as a result of IRP), these markets fall into the low and moder-
ate risk segments in the external risk index. Conversely, while France, Germany 
and the UK pose the greatest external risk (i.e. as a function of the number of 
significant markets referencing them), they fall into the low and moderate risk seg-
ments in the internal risk index. cOnclusiOns: The inversion seen between the 
two risk indices reflects a key aspect of the current IRP landscape. Namely, mature 
markets exert considerable influence on prices internationally, while their use of 
IRP exerts limited downward pressure on their own prices. Conversely, while IRP 
policy in emerging markets is more likely designed to secure the lowest possible 
prices, these markets carry less influence on prices internationally.
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Objectives: HTA processes are being implemented in Latin America in an effort 
for a more efficient resource allocation. The objective of this study was to explore 
the HTA environment and classify its diversity based on previously developed tax-
onomies. This enables the comparison within the region, as well as with other 
regions in which similar maps have been developed, such as Europe. MethOds: 
Two taxonomic groupings were used as described in Allen et al 2013 Health Policy 
113; 305– 312. The first one is based on the position of a national HTA agency in 
relation to the position of the regulatory and the coverage body. The second set 
focuses on the key tasks performed by the HTA agency. The following countries were 
examined: Mexico, Cuba, Costa Rica, Colombia, Venezuela, Ecuador, Peru, Bolivia, 
Brazil, Uruguay, Argentina and Chile. No information on HTA activity could be iden-
tified for the rest of the countries on official websites or publications. Results: 
Seven different archetypes were identified by combining different values of the two 
taxonomic sets in these twelve countries. There were two main groups identified: 
one consisting of Brazil, Cuba and Chile where the HTA and coverage decisions are 
performed by the same agency and regulatory is independent, and the other one 
consisting of Costa Rica, Venezuela, Peru and Bolivia where no HTA process was 
identified and external evaluations or decisions from reference countries are used 
to inform decisions. cOnclusiOns: Although the landscape is expected to change 
in the coming years, this first high-level overview shows that currently, there is a 
high degree of heterogeneity in HTA processes in Latin America despite the fact 
that these countries tend to share expertise in various levels, with few countries 
following similar processes and a number of countries with no HTA bodies in place 
at any decision level.
PHP235
cOmbining HeadROOm and RetuRn On investment analysis tO Rank 
POtential cOmmeRcial value Of six medical devices in develOPment
Markiewicz K.1, van Til J.A.1, Steuten L.M.G.2, IJzerman M.J.3
1University of Twente, MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, 
The Netherlands, 2University of Twente, Enschede, The Netherlands, 3MIRA Institute for 
Biomedical Technology & Technical Medicine and University of Twente, Enschede, The Netherlands
Objectives: The development process of medical devices strongly depends on 
the financial resources available and the expected return on investment to manu-
facturers. The aim of this paper is to analyse the potential commercial viability of 
two disruptive and four incremental medical devices in different stages of develop-
ment. MethOds: The headroom method combined with the return on investment 
analysis was performed for one therapeutic and five diagnostic devices for different 
clinical target areas. Information regarding maximum additional benefit that could 
be obtained with new device, the estimated production price and expected sales 
volume was gathered from literature and expert opinions. A willingness-to-pay 
threshold for one additional QALY of € 30,000 was assumed for headroom analy-
sis. Results: The devices were ranked according to their potential commercial 
viability. The analysis showed that two disruptive and two incremental devices had 
reasonably good balance between headroom and unit cost, and two incremental 
devices had no good balance. The device with the highest potential commercial 
viability was a disruptive therapeutic device for the cartilage repair treatment 
in the first clinical trial stage, with estimated headroom for the cost of the new 
treatment: € 74,600 and an expected production cost of the therapy: € 8,000 per unit. 
The market volume size was calculated based on the incidence of cartilage defects: 
65% in routine knee arthroscopies. The disruptive diagnostic device for home brain 
monitoring of epilepsy patients in the prototype stage of development had the low-
est potential commercial viability, with an estimated headroom of € 81,000 and an 
expected production costs per unit: € 120,000 that resulted in the unfavorable return 
on investment. cOnclusiOns: The headroom method combined with a return on 
investment analysis, offers insight in the potential commercial viability of medical 
devices under development. The research on the impact of that analysis on actual 
R&D decision making will still be determined.
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Objectives: Data availability and decision makers methodology requirements are 
two important factors influencing transferability of economic studies. Applying quali-
tative assessment of experts’ opinion and systematic review of published economic 
studies, we aimed to analyze transferability of economic evaluations in Central and 
Eastern European (CEE) and former Soviet countries. MethOds: Firstly, eleven reim-
bursement experts from eight countries were interviewed on their background and 
current practice of using economic evaluations, opinion regarding transferability 
of economic evaluations and importance of individual Welte’s transferability fac-
tors. Secondly, we analyzed peer-reviewed English-language economic evaluations 
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of sixteen countries from the region according to different criteria: characteristics, 
quality (using Drummond’s checklist), use of local data, addressed inputs limita-
tion and results transferability. Results: Economic evaluations are used in CEE 
countries for informing decision making, while critically considering methodology, 
quality and study’s reliability. Experts acknowledged limited generalizability of study 
results both between and within geographic regions. Meanwhile, despite these con-
straints, facing limited health technology assessment (HTA) capacity experts were 
still using foreign evidence. At the same time, the usefulness of studies published in 
CEE and former Soviet countries to inform their decision making is limited because 
of insufficient transparency in reporting, unaddressed uncertainty, limited insight on 
inputs and transferability of results. Although local costs, baseline risk and resource 
use data are required, experts accept evidence originating from health care settings 
outside CEE and former Soviet countries regarding relative effect and utilities val-
ues. cOnclusiOns: HTA priority setting and transferability assessment of economic 
evidence are important issue in health care decision making in CEE and former Soviet 
countries, since HTA research capacity is limited and local evidence is scarce. For this 
purpose, quality, transparency, and transferability should be addressed explicitly in 
published economic evaluations originating from CEE and former Soviet countries.
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bAckgROund: The Department of Science and Technology (DECIT) at the Ministry 
of Health (MoH), since 2003, has financed studies to support demands from 
the MoH technical areas regarding the decision making process about health 
technologies. Objectives: To analyze DECIT performance in financed Health 
Technology Assessment (HTA) studies to improve the capacity building of HTA in 
Brazil. MethOds: A retrospective descriptive study based on the analysis of docu-
ments and official records built in a single database in Excel containing the studies 
promoted by DECIT from 2003 to November 27, 2013. The variables pre-classified 
and collected from Brazilian Network for Health Technology Assessment’s database, 
SISREBRATS, were revised by two reviewers and conferred or supplemented with data 
from the Database of Health Research, Annual Reports Management by DECIT, and 
Final Reports and Cooperation Agreements by co-financier partners. Results: 284 
HTA projects were financed entirety for R$ 25 million (± R$ 1,69 million) between 2003 
and 2013. The average value financed was R$ 346 thousand and the average bias was 
± RS 61 thousand. Of these, 57% (162/284) are pharmacotherapy; and 35% (99/248) are 
systematic reviews. The majority of the studies 58% (165/284) were financed by MoH 
calls in years 2005 to 2010 and contributed to 110 masters and doctors conclusions in 
HTA landfield. cOnclusiOns: These numbers show despite the HTA culture in Brazil 
having been in its initial stage, DECIT is increasing its capacity to respond to demands 
with a variety of studies types, specily in pharmacotherapy. However, evaluation 
demands do not always correspond to health needs of promotion and prevention.
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Objectives: Since January 2011, pharmaceutical manufacturers are obliged to sub-
mit dossiers presenting benefits over comparative treatment when launching new 
products in the German pharmaceutical market. These dossiers are usually evalu-
ated by the Institute for Quality and Efficiency in Health Care (IQWiG). Based on the 
dossier, the IQWiG’s evaluation and a subsequent hearing process, the Federal Joint 
Committee (G-BA) decides on additional therapeutic benefit related to mortality, 
morbidity, quality of life (QoL) and side effects. As QoL is among the more contested 
of these criteria and remains comparably unspecified, this qualitative study’s aim 
was to analyze definitions and the role of QoL in early assessments of benefit (EAB) 
in Germany. MethOds: As most of the documents are freely available on the G-BA’s 
website, this study included all relevant documents of the first completed 66 assess-
ments (11.2011-12.2013). We conducted a qualitative content analysis screening the 
dossiers, IQWiG evaluations, G-BA decisions and the protocols of the oral hearing for 
relevant links to QoL and synonyms. In a process of independent analysis and joint 
consensus building by two researchers, relevant text passages were extracted and 
reduced to key content on the term’s usage. During analysis, a system of codes was 
developed accounting for a wide variety of recurring QoL-related definitions and 
references to its importance. Results: Even though key players did not necessarily 
share the same QoL-definition, the concept’s relative importance was highlighted in 
numerous references. G-BA decisions criticize the lack of or the inadequate presen-
tation of QoL data in the manufacturer’s dossiers. G-BA and IQWiG apply a narrow 
understanding of QoL, while manufacturers failed to establish wider notions of QoL 
linking factors such as patient satisfaction to the concept. cOnclusiOns: QoL in a 
particular sense is of pivotal importance in Germany’s early assessment of benefit. 
The demand for reliable QoL data is growing.
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Objectives: Advanced-therapy medicinal products (ATMPs), such as gene therapy, 
cell therapy and tissue engineering are a new class of medicines in the EU. ATMPs 
offer prospects in prevention and treatment of fatal and/or chronic debilitating 
diseases where no effective treatments exist. However, with complicated mecha-
nisms of actions and benefits often being anticipated in the longer term, it is chal-
lenging to demonstrate hard clinical evidence and create robust cost-effectiveness 
models that Payers have come to expect at the launch of pharmaceuticals. Thus, 
manufacturers face difficulties when negotiating the price for ATMPs and may not 
be able to realize their full potential. This paper aims to use case studies of ATMPs 
launched in EU5 to outline access pathways and review the clinical and economic 
evidence requirements. MethOds: Secondary research identified ATMP approv-
als since 2008 and a framework was created to develop hypotheses on clinical 
and economic evidence requirements, considering alternative routes to market. 
Hypotheses were then validated during in-depth interviews with key stakeholders 
across EU5. Results: Payers are yet to be convinced about the full benefit of ATMPs 
and are reluctant to pay premium prices if they are not sure about long-term effi-
cacy and safety. Additionally, in their cost-benefit analyses, Payers tend to consider 
only the direct costs associated with a condition, ignoring broader societal benefits 
and savings in the long run. Therefore, price negotiations are sometimes lengthy. 
Risk sharing and novel payment-by-result schemes are often agreed to mitigate 
risks. cOnclusiOns: Payers are not yet familiar with the potential value of ATMPs, 
and, in most cases specific evaluation criteria don’t exist. Manufacturers need to 
invest in educating Payers on the huge differences between ATMPs and traditional 
therapies, particularly to show that manufacturing costs are substantial, and work 
together to identify relevant measures for clinical and economic evaluations of 
this new therapy class.
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Objectives: The Objectives are to present the characteristics of the quick-HTA 
started in June 2013 and to show the Results of the first quick-HTA process in 
Romania. MethOds: The health care context and the Romanian legislation cov-
ering HTA were studied by considering: the reasons behind HTA introduction, the 
key stakeholders and the HTA process. A critical appraisal was done covering public 
HTA reports and the decisions taken by the Ministry of Health (MofH). Results: 
The introduction of quick-HTA began mid-June 2013 when MofH released the leg-
islation and the HTA Unit started receiving dossiers for new drugs/indications. The 
HTA model was based on a “score-card” system with 6 criteria: HAS (France) opinion, 
NICE/SMC/AWMSG (UK) opinion, the number of EU countries with reimbursement, 
relative efficacy, relative safety and relative patient-reported-outcomes (PRO), but no 
role of budget impact. From June to December 2013, 167 HTA dossiers were evaluated 
by the HTA Unit with an acceptance rate of about 80%. Most of the drugs accepted for 
reimbursement were oncological (23%); other main therapeutic areas were diabetes 
with 16 drugs/indications receiving positive evaluations, rheumatology (14), onco-
haematology (8) and neurology (7). The HTA included also biosimilars, all 4 of them 
receiving positive decisions. Unfortunately, early 2014, the new Government abrogated 
this HTA legislation and the already-published HTA reports, claiming that the process 
didn’t mentioned the criteria for de-listing reimbursed drugs nor the budget impact, 
within HTA reports. Moreover, the HTA process was moved into the responsibility of 
the National Agency for Drugs. cOnclusiOns: The implementation of the quick-HTA 
in Romania took a good start, using a mixture of information, from benefits and cost-
effectiveness in other countries, to relative effectiveness, safety and PRO. However, 
the lack of consideration for the local context and the political disagreements led to 
a temporary suspension of this quick-HTA process in Romania.
PHP242
Hta in tHe bRazilian HealtH caRe system and POtential lessOns 
leaRned fOR OtHeR bRics states
Stuwe L.T.1, Bellanger M.M.2, Picon PD.3
1Pierre-and-Marie-Curie University, Paris, France, 2EHESP French School of Public Health, Rennes, 
France, 3Federal University of Rio Grande do Sul, Porto Alegre - RS, Brazil
Objectives: The objective of the study was to provide an external assessment 
of recent HTA institutionalization in Brazil, and identify a set of lessons learned 
potentially applicable to BRICS States. MethOds: This research is based on a quan-
titative and qualitative assessment. A literature survey between 2000 and 2014 was 
conducted in English, Spanish and Portuguese in PubMed/Medline, Science Direct, 
LILACS and SciELO. Epidemiological and socio-economic data was retrieved from 
national health accounts as well as WHO/PAHO, OECD and World Bank. For the 
Brazilian National Committee for Incorporation of Technologies (CONITEC), avail-
able reports on the incorporation of medicines into the National Unified System 
(SUS) for the first two years of operation (2012 and 2013) were analyzed. A matrix 
containing quantitative and qualitative criteria was elaborated to analyze reports 
by the outcome of decision, therapeutic class, author (s) of the request and public 
consultation. Results: A total of 92 available CONITEC reports for 2012 (n= 38, 33 
for medicines) and 2013 (n= 54, 42 for medicines) were analyzed. 45% of reports on 
medicines recommended incorporation into the SUS. Most of the positive recom-
mendations were clearly related to public health priorities as identified by the gov-
ernment, translating a strong commitment for improved access to medicines within 
the SUS i.e. anti-cancer drugs. Overall, the creation of the CONITEC represents a 
substantial step toward the institutionalization of HTA, with more transparency 
and accountability in decision-making processes, considering ethical, organiza-
tional, social, and legal aspects. cOnclusiOns: Whereas lowest in Russia, India 
and South Africa, and at a transitional stage in China, Brazil has a comparable 
degree of institutionalization of HTA as countries with a long-lasting HTA experi-
ence. A best-practice assessment in the area of HTA within the BRICS has still to be 
elaborated. Transferability of lessons learned might be a strong tool for improving 
HTA development within the BRICS.
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